Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ699MR)

This product GTTS-WQ699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14592MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ7542MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ10447MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ351MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ9602MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ15031MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ7721MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW